Acceptability of Artificial Intelligence in the Diagnosis of Prostate Cancer

Brief summary (registry, in English)

This study investigates the acceptability of artificial intelligence (AI) as a diagnostic support tool among patients with localized prostate cancer and healthcare providers, as well as their willingness to share health data for AI development. Background AI tools in healthcare show promising potential, especially in improving diagnosis accuracy and personalizing treatment. However, successful implementation depends not only on technical performance but also on the acceptability of AI among its users-both patients and professionals. Prior research has shown varied acceptability depending on context, disease severity, task performed by AI, and user population. Objectives Assess patients' acceptability of AI as a diagnostic support in prostate cancer. Explore patients' willingness to share health data for developing clinical AI. Assess healthcare providers' acceptability of AI in this diagnostic context. Methodology Design: A cross-sectional, mixed-method, multinational study (Belgium, Italy, Spain). Quantitative Phase: Online questionnaire, using adapted theoretical frameworks (Value Perception Model, NASSS-AI, TFA). Qualitative Phase: Will follow based on quantitative findings. Participants: Adults diagnosed with localized prostate cancer. Recruitment via hospitals, social media, and patient associations. Data Collected: Personal and health information, attitudes toward AI, willingness to share data. Ethics Approved by ethics committees in each participating country. Informed consent obtained digitally before participation. Data anonymized and GDPR-compliant.

What you commit to

• Study type: Interventional
• Participants enrolled: 51
• From 2 Dec 2024 to the primary completion date, 31 Dec 2025
• 1 site in 1 country
• Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Who the study is looking for

Age in the registry: 18 years to - · Sex: Male · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (1)

Sites in registry order. Pick your city on the disease page to sort them by distance.